• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗器械证据开发计划覆盖的实施:晚期技术采用国的决策工具。

Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.

机构信息

Syreon Research Institute, Budapest, Hungary.

Center for Health Technology Assessment and Pharmacoeconomic Research, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.

出版信息

Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):195-206. doi: 10.1002/hec.4504. Epub 2022 Mar 23.

DOI:10.1002/hec.4504
PMID:35322478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9543994/
Abstract

Experiences with coverage with evidence development (CED) schemes are fairly limited in Central and Eastern European (CEE) countries, which are usually late adopters of new health technologies. Our aim was to put forward recommendations on how CEE health technology assessment bodies and payer organizations can apply CED to reduce decision uncertainty on reimbursement of medical devices, with a particular focus on transferring the structure and data from CED schemes in early technology adopter countries in Western Europe. Structured interviews on the practices and feasibility of transferring CED schemes were conducted and subsequently, a draft tool for the systematic classification of decision alternatives and recommendations was developed. The decision tool was reviewed in a focus group discussion and validated within a wider group of CEE experts in a virtual workshop. Transferability assessment is needed in case of (1) joint implementation of a CED scheme; (2) transferring the structure of an existing CED scheme to a CEE country; (3) reimbursement decisions that are linked to outcomes of an ongoing CED scheme in another country and (4) real-world evidence transferred from completed CED schemes. Efficient use of available resources may be improved by adequately transferring evidence and policy tools from early technology adopter countries.

摘要

在中东欧(CEE)国家,有证据的药物开发(CED)方案的经验相当有限,这些国家通常是新技术的后期采用者。我们的目的是提出建议,说明 CEE 卫生技术评估机构和支付者组织如何应用 CED 来减少医疗器械报销决策的不确定性,特别关注从西欧早期技术采用者国家的 CED 方案中转移结构和数据。对 CED 方案的实践和可行性进行了结构化访谈,随后开发了一个用于系统分类决策替代方案和建议的工具草案。该决策工具在焦点小组讨论中进行了审查,并在一个虚拟研讨会上由更广泛的 CEE 专家群体进行了验证。在以下情况下需要进行可转移性评估:(1) 联合实施 CED 方案;(2) 将现有 CED 方案的结构转移到 CEE 国家;(3) 与另一个国家正在进行的 CED 方案结果相关的报销决策;(4) 从已完成的 CED 方案中转移真实世界证据。通过从早期技术采用者国家充分转移证据和政策工具,可以提高现有资源的使用效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a6/9543994/3a82ba0cfe04/HEC-31-195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a6/9543994/f81eef8beb83/HEC-31-195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a6/9543994/3a82ba0cfe04/HEC-31-195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a6/9543994/f81eef8beb83/HEC-31-195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a6/9543994/3a82ba0cfe04/HEC-31-195-g002.jpg

相似文献

1
Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.医疗器械证据开发计划覆盖的实施:晚期技术采用国的决策工具。
Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):195-206. doi: 10.1002/hec.4504. Epub 2022 Mar 23.
2
Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.医疗设备在中东欧的 HTA 走向何方?解决方法学挑战的建议。
Front Public Health. 2021 Jan 8;8:612410. doi: 10.3389/fpubh.2020.612410. eCollection 2020.
3
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.医疗器械的证据开发计划的覆盖范围在欧洲:特点和挑战。
Eur J Health Econ. 2021 Nov;22(8):1253-1273. doi: 10.1007/s10198-021-01334-9. Epub 2021 Jun 12.
4
Coverage with evidence development for medical devices in Europe: Can practice meet theory?医疗器械的证据开发覆盖范围在欧洲:实践能否符合理论?
Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):179-194. doi: 10.1002/hec.4478. Epub 2022 Feb 26.
5
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.在中东欧国家,关于患者参与卫生技术评估的建议。
Front Public Health. 2023 Jul 3;11:1176200. doi: 10.3389/fpubh.2023.1176200. eCollection 2023.
6
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.克服人工智能驱动的证据在健康技术评估中应用障碍的建议。
Front Public Health. 2023 Apr 26;11:1088121. doi: 10.3389/fpubh.2023.1088121. eCollection 2023.
7
Delayed payment schemes in Central-Eastern Europe and Middle-East.中东欧和中东的延迟支付计划。
Front Med (Lausanne). 2022 Aug 12;9:940371. doi: 10.3389/fmed.2022.940371. eCollection 2022.
8
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making.关于在中东欧卫生政策决策中使用来自西欧的真实世界证据的指南。
J Comp Eff Res. 2023 Apr;12(4):e220157. doi: 10.57264/cer-2022-0157. Epub 2023 Mar 2.
9
Coverage with evidence development: the Ontario experience.循证医保覆盖:安大略省的经验。
Int J Technol Assess Health Care. 2011 Apr;27(2):159-68. doi: 10.1017/S0266462311000018.
10
Coverage with Evidence Development: applications and issues.有证据开发的保险覆盖:应用和问题。
Int J Technol Assess Health Care. 2010 Jan;26(1):79-85. doi: 10.1017/S0266462309990882.

引用本文的文献

1
Domains and Methods of Medical Device Technology Evaluation: A Systematic Review.医疗器械技术评估的领域与方法:一项系统综述
Public Health Rev. 2024 Jul 24;45:1606343. doi: 10.3389/phrs.2024.1606343. eCollection 2024.
2
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.克服医院健康技术评估(HB-HTA)中的障碍:国际专家小组共识
Healthcare (Basel). 2024 Apr 25;12(9):889. doi: 10.3390/healthcare12090889.
3
Knowledge management tools and mechanisms for evidence-informed decision-making in the WHO European Region: a scoping review.

本文引用的文献

1
Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development.创新型医疗技术在德国住院医疗中的实施:利用模式和证据开发。
Implement Sci. 2021 Oct 30;16(1):94. doi: 10.1186/s13012-021-01159-3.
2
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.医疗器械的证据开发计划的覆盖范围在欧洲:特点和挑战。
Eur J Health Econ. 2021 Nov;22(8):1253-1273. doi: 10.1007/s10198-021-01334-9. Epub 2021 Jun 12.
3
Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
知识管理工具和机制在世界卫生组织欧洲区域循证决策中的应用:范围综述。
Health Res Policy Syst. 2023 Oct 31;21(1):113. doi: 10.1186/s12961-023-01058-7.
4
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making.关于在中东欧卫生政策决策中使用来自西欧的真实世界证据的指南。
J Comp Eff Res. 2023 Apr;12(4):e220157. doi: 10.57264/cer-2022-0157. Epub 2023 Mar 2.
5
Coverage with evidence development for medical devices in Europe: Can practice meet theory?医疗器械的证据开发覆盖范围在欧洲:实践能否符合理论?
Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):179-194. doi: 10.1002/hec.4478. Epub 2022 Feb 26.
医疗设备在中东欧的 HTA 走向何方?解决方法学挑战的建议。
Front Public Health. 2021 Jan 8;8:612410. doi: 10.3389/fpubh.2020.612410. eCollection 2020.
4
[Policy developments of health technology assessment in the European Union].[欧盟卫生技术评估的政策发展]
Postepy Biochem. 2019 Nov 29;65(4):319-321. doi: 10.18388/pb.2019_285.
5
Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices.欧洲医疗器械卫生技术评估健康经济指南的批判性综述
Front Med (Lausanne). 2019 Nov 29;6:278. doi: 10.3389/fmed.2019.00278. eCollection 2019.
6
Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.欧洲患者获取医疗器械的障碍和促进因素:系统文献回顾。
Health Policy. 2019 Dec;123(12):1185-1198. doi: 10.1016/j.healthpol.2019.10.002. Epub 2019 Oct 19.
7
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.治疗和/或比较效果的真实世界数据研究的良好实践:ISPOR-ISPE联合特别工作组关于医疗保健决策中真实世界证据的建议。
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297.
8
Specific barriers to the conduct of randomised clinical trials on medical devices.医疗器械随机临床试验实施的特定障碍。
Trials. 2017 Sep 13;18(1):427. doi: 10.1186/s13063-017-2168-0.
9
The Role of Learning in Health Technology Assessments: An Empirical Assessment of Endovascular Aneurysm Repairs in German Hospitals.学习在卫生技术评估中的作用:德国医院血管内动脉瘤修复术的实证评估
Health Econ. 2017 Feb;26 Suppl 1:93-108. doi: 10.1002/hec.3466.
10
Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.表征医疗器械评估中的不确定性并确定未来研究需求。
Health Econ. 2017 Feb;26 Suppl 1:109-123. doi: 10.1002/hec.3467.